Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1072 | 1025 | 1114 | 1069 | 1237 | 1575 |
Fund Return | 7.23% | 2.46% | 11.38% | 2.25% | 4.34% | 4.65% |
Place in category | - | - | - | - | - | - |
% in Category | - | - | - | - | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU1993786604 | 1.3B | 11.14 | -12.62 | - | ||
LU1038902927 | 399.8M | 7.23 | 2.25 | 4.65 | ||
LU1046463953 | 399.8M | 7.23 | 2.12 | 4.61 | ||
UBSLuxEq GlblIncomeUSD SGD H Pmdist | 392.08M | 14.74 | 7.18 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Allianz Income Growth AM H2 | 49.96B | 6.35 | -0.39 | 5.89 | ||
LU0912757837 | 17.58B | 7.81 | 1.12 | 3.37 | ||
FirstEagleAmundi IntlClassAHSQDShrs | 6.05B | 11.48 | 3.82 | 4.84 | ||
FirstEagleAmundi IntlClassAHSC Shrs | 6.05B | 14.50 | 5.64 | 5.05 | ||
LU1391767313 | 339.93M | 1.86 | -3.17 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UBS (Lux) BFConvert Eurp EUR U-X EUR Inc | LU0415180149 | 18.75 | - | - | |
UBS Lux Equity SICAV - European Opportunity Uncons | LU0549584711 | 18.34 | 41,518.270 | -0.93% | |
UBS(LUX) ES Eurp Hi DivSsEUR U-X-acc | LU0566497789 | 14.58 | - | - | |
UBS Lux Bond SICAV - Convert Global EUR I-X-dist | LU0396332644 | 14.46 | 186.170 | +0.15% | |
Teva Pharmaceutical Finance Netherlands II B.V 7.375% | XS2592804434 | 0.63 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review